Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.novartis.com › es-esNovartis

    27 de may. de 2024 · Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  2. prod1.novartis.comNovartis

    Hace 2 días · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

  3. Videos

    Ver todo

  4. www.novartis.com › news › media-releasesNovartis atrasentan Phase III data show clinically meaningful ...

    25 de may. de 2024 · Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1.

  5. www.novartis.com › news › media-releasesNovartis highlights pioneering innovation in CML with data ...

    15 de may. de 2024 · Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA. May 15, 2024. Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ...

  6. www.novartis.com › healthcare-professionalsASCO 2024 | Novartis

    15 de may. de 2024 · ASCO 2024. At ASCO this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research.

  7. prod1.novartis.com › us-en › newsNovartis Scemblix® Phase III data first to show superior ...

    31 de may. de 2024 · Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML. May 31, 2024. Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib ...

  8. www.bolsamania.com › accion › NovartisCotización de Novartis: Acciones e información - Bolsamania

    29 de may. de 2024 · Novartis gana un 16% más hasta septiembre y mejora previsiones tras la escisión de Sandoz

  1. Búsquedas relacionadas con novartis

    novartis méxico
    novartis farmacéutica
    novartis contacto
    novartis careers
    novartis bolsa de trabajo
    novartis productos
    novartis logo
    novartis tienda
    novartis registro de pacientes
    novartis tarjeta de descuento
    novartis empleos
    novartis pharmaceuticals
  2. Otras búsquedas realizadas